iPS cell Generation patent landscape - 2013/03

NEW YORK, May 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

iPS cell Generation patent landscape - 2013/03
http://www.reportlinker.com/p01171945/iPS-cell-Generation-patent-landscape---2013/03.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged tissues using differentiated cells out of stem cells. However, ethical and scientific issues are related to the use of embryonic stem cells. In this context, induced pluripotent stem cells (iPS) appear as a promising approach. The patient's somatic cells are first dedifferentiated into iPS cells and then redifferentiated into the cell of interest. This revolutionary technology represents major scientific, societal and economic challenges and was recently rewarded by a Nobel Prize in Physiology and Medicine to Prof. Shinya Yamanaka and Prof. John Gurdon.

With over 1000 patent families qualified and analyzed out of a pool of 3000 patent families, we have analysed:

- The "iPS cells generation" patent landscape
The analysis of this patent landscape shows a strong complexity of the environment and demonstrates the ability of institutional players to develop a consistent IP strategy like the one from Kyoto university. Some major players already present in 2011 increased sharply their filings: the Kyoto university, the Chinese Academy of Sciences, the laboratories of US government. New entrants have filed numerous patent applications in the last years: Korea university, AIST, Cellular Dynamics, Salk Institute and A*STAR (SG).

- The "iPS cells differentiation" patent landscape
As for the thematic "iPS cells generation", the main players are mainly institutional (23 institutional applicants in the top 30) with the university of Kyoto and the laboratories of the US government at the first two places. However, industrial applicants from all over the world clearly positioned themselves on the thematic such as Cellular Dynamics (US), Cellectis (FR) or Viacyte (US).

The technological breakdowns presented in this study had shown specific positioning of the players through their patent applications notably regarding the type of cell obtained from the differentiation of iPS cells. Cardiovascular, neural, pancreatic cells are the most claimed by the applicants, this corresponding to the main pathologies observed nowadays. Hepatic cells are also often claimed notably for the establishment of toxicology studies.

- The "iPS cells database"
Additionally, all patents dealing with iPS cells but who were concerning neither generation nor differentiation (thus all patents related to culture, selection, isolation, etc…) were grouped together in a database to get a full overview of the iPS landscape.

These patent landscapes provide you a comprehensive panorama of the intellectual property overview and help you:
* Identify key inventors and players involved in the generation and differentiation of iPS cells
* Understand their positioning, the collaboration networks and their dynamics
* Analyze their IP strategy
* Position your company's R&D and IP portfolio·
* Discover new trends and emerging topics

A three months access to the corresponding patent database, dynamic and interactive, is also included.

Table of contents

Generalities
Brief outline of the technology: generation and source of stem cells
Brief outline of the technology: reprogramming techniques
Global search strategy of patents and patent applications related to iPS cells

Evolution and location of patent filings
Evolution of patent filings (1999-2013)
Map and evolution of priority filings
Map of extensions

Analysis of patent applicants
Main applicants on the entire period (1999-2013)
Part of the portfolio hold by the first 10 applicants
Breakdown of filings of the main institutional/industrial applicants over time
Main co-filings between applicants
Applicants and their affiliates

Analysis of inventors
List of the main inventors
Main research teams

Breakdown of the patent portfolio
Breakdown of the portfolio (for each breakdown are presented the distribution of technologies, the evolution of filings and the positioning of institutional applicants, industrial applicants and inventors)
Breakdown of the portfolio:
1/ Origin of cell to be reprogrammed
2/ Type of cell to be reprogrammed
3/ iPS cells generation technique
4/ Type of reprogramming factor 1
5/ Type of reprogramming factor 2
6/ Method of delivery

Citation, extension & granted analysis
List of the most cited patents and patent applications
List of the most extended patents & patent applications
Granted and not granted patents filed by institutional/industrial applicants by office

Applicant focuses
Kyoto university
Chinese Academy of Sciences
US government
Harvard university
Korea university
Cellular dynamics
Whitehead biomedical institute
Advanced Industrial Science and Technology
California university

Conclusive comments

To order this report:
Biological_Therapy Industry: iPS cell Generation patent landscape - 2013/03

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker